Our Board of Directors

Professor Evis Sala

CMO & Co-Founder
Medical Advisory Board Chair

Evis has focused on research and clinical applications of AI in cancer imaging since 2018, and co-founded Lucida Medical with Antony Rix in 2019.

Prof Evis Sala, Chief Medical Officer and Co-Founder, is internationally recognised for her academic and clinical work in cancer imaging, where she has helped pioneer the use of MRI for oncology. A board-certified Consultant Radiologist, she is the Chair of the Department of Diagnostic Imaging and Radiotherapy at the Fondazione Policlinico Universitario A. Gemelli, IRCCS and Professor of Radiology at the Università Carolina del Sacro Cuore in Rome, leading a large combined clinical and academic department. She was previously Professor of Oncological Imaging at the University of Cambridge, and Chief of Body Imaging Service at Memorial Sloan Kettering Cancer Centre, New York.

Dr Antony Rix

CEO and Co-Founder

Antony Rix, CEO, Lucida Medical, has over 25 years’ experience in AI and software. His PhD research on AI in telecommunications won an international standards competition in 2001 and is still in use today. After 12 years developing communications systems and medical devices at technology consultancy TTP, he returned to startups in 2016. Antony has focused on applying his expertise in AI and medical technology to cancer since 2018, and in 2019 co-founded Lucida Medical with Prof Evis Sala to commercialise this. Antony initially led the development of the company’s Pi technology and now supports hospitals to adopt it.

Dr David Tuch

Chair of the Board

Dr David Tuch, Chair, has substantial track-record in technology development and commercialisation both in start-ups and industry. David received his PhD from MIT and Harvard Medical School working in MRI, inventing and patenting a pioneering method for diffusion-weighted imaging now used worldwide. After serving as Global Head of Imaging at Novartis and then as Head of Research Alliances at GE Healthcare, David founded Lightpoint Medical to develop a novel miniaturised gamma ray sensor for surgery for prostate cancer and other conditions. He successfully developed and led the company through to an exit to Telix Pharmaceuticals in 2023.

David has supported Lucida Medical since 2021.

Medical Advisory Board

Prof Anwar R. Padhani

Medical Advisory Board

Prof. Anwar R. Padhani is an internationally recognized radiologist and key opinion leader in AI for prostate imaging. He leads MRI and imaging research at the Paul Strickland Scanner Centre at Mount Vernon Cancer Centre and is a professor at the Institute of Cancer Research in London. His work focuses on advanced MRI techniques in cancer care, including functional imaging of prostate, breast, and rectal cancers. He is Co-Chair of the International Prostate Imaging Reporting and Data System (PI-RADS) Steering Committee and advises organisations such as the US National Cancer Institute and Cancer Research UK on imaging in clinical trials.

David has supported Lucida Medical since 2021.

Prof Jochen Walz

Medical Advisory Board

Prof. Jochen Walz is head of urology at the Institut Paoli-Calmettes Cancer Centre in Marseille and Associate Professor in Urology. He trained in Germany and France, became board certified in 2005, and completed a research fellowship at the University of Montreal. His work focuses on prostate cancer, imaging and prediction tools.

His research focuses on prostate cancer, imaging, prediction tools, and minimally invasive surgery. He is Co-Editor-in-Chief of European Urology Open Science and active in several professional societies, including the European Association of Urology and the American Urological Association.

Leadership Team

Mark Hinton

CTO

Mark Hinton previously built Image Analysis Group from 6 people to a 40-person clinical research organisation with multi million revenues. Mark brings over 30 years’ expertise in software and technology development, building and running international teams, and delivering substantial, profitable growth.

Lucy Davies

VP Clinical

Lucy Davies, MBA MPH, is VP Clinical at Lucida Medical and an NHS Innovation Accelerator Fellow. She has a background in clinical research and previously led the development of prostate cancer and other clinical trials at the Surgical Intervention Trials Unit, University of Oxford.

Corina Cucuruzac

VP Sales & Marketing

Corina Cucuruzac is a commercial leader with extensive experience in sales, marketing, and global market expansion across multinational corporations, startups, and scale-ups in the MedTech industry. With an MBA and an LLM in European Commercial Law, Corina combines strategic insight with business acumen to drive impactful growth. She has successfully led commercial strategies in both large multinational organizations and fast-growing startups such as Terumo Europe, Oncomfort, OncoDNA, and other companies where she successfully managed international distributor networks, international sales and marketing teams and spearheaded strategic growth initiatives.

At Lucida Medical, she leads commercial strategy, advancing our solution through innovative market positioning and strategic partnerships, ensuring sustainable growth and industry leadership.